Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.
Microplate Dx has raised $645K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2025.
Microplate Dx's investors include University of Strathclyde, Scottish Enterprise, Deepbridge Capital, SIS Ventures, Thairm Bio.
Microplate Dx is headquartered in Glasgow, United Kingdom.
Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.
Microplate Dx is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Microplate Dx — Funding & Investors." VCBacked, September 8, 2025, https://www.vcbacked.co/company/microplate-dx. Accessed October 6, 2026.
VCBacked. (2025). Microplate Dx — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/microplate-dx
{{cite web |title=Microplate Dx — Funding & Investors |url=https://www.vcbacked.co/company/microplate-dx |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated